BeiGene Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de BeiGene de 60.7% y 19% por año respectivamente. Se prevé que el BPA crezca en un 63.6% al año. Se espera que la rentabilidad financiera sea de 14.1% en 3 años.

Información clave

59.7%

Tasa de crecimiento de los beneficios

63.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	19.2%
Rentabilidad financiera futura	13.0%
Cobertura de analistas	Good
Última actualización	29 Jul 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:BGNE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5,047	225	268	673	23
12/31/2025	4,037	-335	-421	-125	28
12/31/2024	3,205	-841	-790	-584	28
3/31/2024	2,763	-784	-1,566	-902	N/A
12/31/2023	2,459	-882	-1,754	-1,157	N/A
9/30/2023	2,204	-959	-1,853	-1,254	N/A
6/30/2023	1,811	-1,732	-2,283	-1,738	N/A
3/31/2023	1,557	-1,917	-2,298	-1,824	N/A
12/31/2022	1,416	-2,004	-1,966	-1,497	N/A
9/30/2022	1,250	-2,149	-2,144	-1,686	N/A
6/30/2022	1,069	-2,030	-2,016	-1,620	N/A
3/31/2022	877	-1,960	-2,044	-1,660	N/A
12/31/2021	1,176	-1,458	-1,614	-1,299	N/A
9/30/2021	1,062	-1,340	-1,334	-1,123	N/A
6/30/2021	947	-1,327	-1,193	-974	N/A
3/31/2021	863	-1,167	-1,030	-816	N/A
12/31/2020	309	-1,625	-1,510	-1,283	N/A
9/30/2020	266	-1,512	-1,426	-1,218	N/A
6/30/2020	225	-1,394	-1,301	-1,137	N/A
3/31/2020	402	-1,145	-1,093	-920	N/A
12/31/2019	428	-949	-909	-750	N/A
9/30/2019	430	-829	-876	-677	N/A
6/30/2019	434	-665	-747	-544	N/A
3/31/2019	244	-737	-787	-615	N/A
12/31/2018	198	-674	-689	-548	N/A
9/30/2018	158	-505	-344	-260	N/A
6/30/2018	324	-243	-189	-121	N/A
3/31/2018	271	-147	-129	-56	N/A
12/31/2017	238	-93	N/A	13	N/A
9/30/2017	220	-31	N/A	-107	N/A
6/30/2017	N/A	-184	N/A	-138	N/A
3/31/2017	0	-148	N/A	-105	N/A
12/31/2016	1	-119	N/A	-90	N/A
9/30/2016	6	-109	N/A	-80	N/A
6/30/2016	7	-87	N/A	-66	N/A
3/31/2016	8	-69	N/A	-56	N/A
12/31/2015	9	-57	N/A	-40	N/A
9/30/2015	6	-34	N/A	-34	N/A
6/30/2015	11	-29	N/A	-19	N/A
3/31/2015	12	-26	N/A	-11	N/A
12/31/2014	13	-18	N/A	-9	N/A
12/31/2013	11	-7	N/A	4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BGNE sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que BGNE sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que BGNE sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (19% al año) de BGNE crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 19% al año) de BGNE crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de BGNE sea baja dentro de 3 años (14.1%).

BeiGene Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2026

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall by 18%

Price target increased to US$290

Recent updates

BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024

Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

First quarter 2024 earnings released: US$2.41 loss per share (vs US$3.35 loss in 1Q 2023)

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold US$7.5m worth of stock

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Co-Founder notifies of intention to sell stock

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Full year 2023 earnings released: US$8.45 loss per share (vs US$19.43 loss in FY 2022)

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Now 21% undervalued after recent price drop

Beigene, Ltd. Announces Board Changes

Now 22% undervalued after recent price drop

Forecast to breakeven in 2026

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Co-Founder notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Consensus EPS estimates fall by 18%

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

New minor risk - Profitability

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.51 loss in 2Q 2022)

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Shareholder dilution

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma

Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc

Now 20% undervalued after recent price drop

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Announces Presentations At the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

President recently sold US$1.8m worth of stock

President notifies of intention to sell stock

Consensus EPS estimates fall by 18%

Beigene, Ltd. Provides Update Regarding Recent Business Developments

First quarter 2023 earnings: EPS exceeds analyst expectations

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)